RESUMEN
OBJECTIVE: To explore changes of serum adiponectin and insulin resistance in patients with endometrial cancer and to evaluate the clinical significance and correlation. METHODS: The serum levels of adiponectin and fasting insulin were determined by ELISA, electro-chemilluminometry and radioimmunoassay in 35 patients with endometrial cancer [all patients divided into two groups, A1 group belonged to without postmenopausal when first visiting (n = 20), A2 group belonged to postmenopausal when first visiting (n = 15)] and 30 cases of health control. The result of homeostasis model assessment-insulin resistance (HOMA-IR) index was calculated. RESULTS: The levels of adiponectin in A1 group was lower than that of health control group [(6.7 ± 1.1) versus (10.0 ± 1.4) ng/L, P < 0.05], and HOMA-IR was higher than that of health control group (3.5 ± 1.8 versus 1.1 ± 0.7, P < 0.05). While there were not significant difference between A2 group and health control group (P > 0.05). Adiponectin and insulin resistance was negatively correlated (r = -0.389, P < 0.05). CONCLUSION: Adiponectin reducing and insulin resistance in reproductive age patients may be the independent factors to promote endometrial cancers.